Werfen Annual report 2018

Rate this item
(0 votes)

Our FY2018 Financial report is available on the following LINK, but we would like to take advantage of our Newsletter to share with you the most relevant facts of it:

Delivery of Results

Rate this item
(0 votes)

In continuation with our "Connecting Value" meeting in April in Rome, we wanted to share amazing news regarding Hemostasis, Autoimmunity and Acute Care Diagnostics Lines and our collective ability as part of the EEMEAI world to continuously Deliver Results.  

ValueSelling: the EEMEAI experience

Rate this item
(0 votes)

In the Healthcare Industry, IVD remains pivotal and, as such, the growth of the IVD Market is expected to continue in the next decade. Despite the growth, the IVD sector will be facing important challenges:

Blood Gas Tender – South Africa

Rate this item
(0 votes)

Werfen EEMEAI together with ILEX South Africa have successfully renewed and expanded the current Blood Gas business at one of the largest private pathology groups in South Africa.

GEMweb Plus 500 experience

Rate this item
(1 Vote)

Five o' clock in the morning and time to get up...we have to avoid traffic to access Nairobi, although I am already awake since 4.30 AM thanks to the croaking of a frog. 

I remember that the first time I heard it, I found it to be scary, exactly as the sound of a huge and dangerous flying dinosaur that I saw in a movie many years ago, but as Plutarch reminds us: “the novelty often falsely attributes to what we fear properties that do not possess…”

First Integrated Lab in Finland!

Rate this item
(0 votes)

Oh my gosh!!! … Those were my first words when I saw the results of a tender we had just won. I acted like my 8 and 6year old daughters on Christmas. I screamed (inside of course), jumped up and down and danced my own private victory dance. I was super happy and excited. Finland would have its first Integrated Lab in Tampere. YES!

 

All rights reserved. © werfen.com

Get in touch

with the EEMEA team:

eemea@werfen.com

 

werfenplain

Issues

Go to top